High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B.
about
Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Development and external validation of a clinical prognostic score for death in visceral leishmaniasis patients in a high HIV co-infection burden area in Ethiopia.Cell death and ultrastructural alterations in Leishmania amazonensis caused by new compound 4-Nitrobenzaldehyde thiosemicarbazone derived from S-limonene.Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects.Ending neglect of older people in the response to humanitarian emergencies.Liposomal amphotericin B as a treatment for human leishmaniasisLeishmaniasis: new insights from an old and neglected disease.Immunity to visceral leishmaniasis: implications for immunotherapy.VOSalophen: a vanadium complex with a stilbene derivative-induction of apoptosis, autophagy, and efficiency in experimental cutaneous leishmaniasis.Acyclic Sesquiterpenes from the Fruit Pericarp of Sapindus saponaria Induce Ultrastructural Alterations and Cell Death in Leishmania amazonensis.A clinical severity scoring system for visceral leishmaniasis in immunocompetent patients in South Sudan.Travelers with cutaneous leishmaniasis cured without systemic therapy.The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
P2860
Q30275257-ED12CD6D-80FF-47A0-B97C-34DDB5286528Q33764787-446CC4E9-3997-47A8-B5B9-68F2512AD912Q34301130-6851C622-8F59-4BDF-B787-F1461425145AQ34328882-F63E49CF-8A66-47E4-B0D7-97614CF411FDQ34524561-FD08950F-04C9-46B6-86A6-FA7B5037975EQ36456032-26756792-5511-4879-ABE9-D92888E91878Q37870821-35440773-C780-4829-8A47-21B377E68555Q38243220-6FF9B7D4-4907-4188-BE9C-225B0EB3E03DQ38735051-0119D59C-FE47-48B5-89A4-89F4DB6D4F7AQ41622717-D2A0F80C-F0C2-41B8-8469-B7C9974691E9Q41992292-AEA4A5C9-A26E-4F95-AA8D-18A73E3C87A4Q45802306-C7FF8A85-6325-48D0-AB75-D4567CBF39C1Q55482423-C5A6A5D3-CC7B-439B-AD26-B45FA243FE45Q58856680-6BE0F553-74A0-41C0-853D-ACC0B756FC1E
P2860
High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
High mortality among older pat ...... h to liposomal amphotericin B.
@en
High mortality among older pat ...... h to liposomal amphotericin B.
@nl
type
label
High mortality among older pat ...... h to liposomal amphotericin B.
@en
High mortality among older pat ...... h to liposomal amphotericin B.
@nl
prefLabel
High mortality among older pat ...... h to liposomal amphotericin B.
@en
High mortality among older pat ...... h to liposomal amphotericin B.
@nl
P2860
P50
P356
P1476
High mortality among older pat ...... h to liposomal amphotericin B.
@en
P2093
Dagemlidet T Worku
Koert Ritmeijer
P2860
P304
P356
10.1128/AAC.01298-10
P407
P577
2010-11-15T00:00:00Z